InsidersTradesSigma
Track the TELEFLEX INC share price and the full management transaction log of the company, a listed issuer based in United States. Shares are quoted on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, TELEFLEX INC has published 154 public disclosures. Market capitalisation: €5.8bn. The latest transaction was reported on 5 March 2026 (Attribution). Among the most active insiders: Kelly Liam. Every trade is openly available.
154
Insider Decl.
n/a
Thresholds
€653,233
6 ops.
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate TELEFLEX INC Hold (neutral), based on 11 analysts. Average price target: US$151.36.
52Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,981 of 29,065 companies
28.8
score / 100
Value29
Quality28
FCF yld4.4%
Earn yld-16%
EV/EBITDA27.5x
ROE-0.7%
Gross mgn56%
Net mgn-45%
Debt/EBITDA9.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 5 March 2026
Declarations154 total
3,262 shares0Common StockSEC:0001838834-26-000004:0
3,262 shares0Common StockSEC:0001804149-26-000004:0
4,604 shares0Common StockSEC:0001706189-26-000004:0
2,447 shares0Common StockSEC:0001627036-26-000004:0
231 shares@ US$122.0625.1% of flowCommon StockSEC:0000096943-26-000027:0
396 shares@ US$122.066.2% of flowCommon StockSEC:0000096943-26-000025:0
484 shares@ US$122.068.5% of flowCommon StockSEC:0000096943-26-000023:0
661 shares@ US$122.0623.3% of flowCommon StockSEC:0000096943-26-000021:0
443 shares0Common StockSEC:0001838834-26-000002:0
354 shares0Common StockSEC:0001804149-26-000002:0
161 shares0Common StockSEC:0001706189-26-000002:0
352 shares0Common StockSEC:0001627036-26-000002:0
12,325 shares0Common StockSEC:0001256144-26-000002:0
1,000 shares@ US$115.8612.6% of flowCommon StockSEC:0000096943-25-000130:0
Canonical exit: 3 Nov 2025 (T+90)
1,000 shares@ US$115.2542.3% of flowCommon StockSEC:0000096943-25-000127:0
Canonical exit: 3 Nov 2025 (T+90)
1,500 shares@ US$115.071.6% of flowCommon StockSEC:0000096943-25-000126:0
Canonical exit: 3 Nov 2025 (T+90)
1,500 shares@ US$115.00100.0% of flowCommon StockSEC:0000096943-25-000125:0
Canonical exit: 3 Nov 2025 (T+90)
200 shares@ US$114.78100.0% of flowCommon StockSEC:0000096943-25-000124:0
Canonical exit: 4 Nov 2025 (T+90)
1,051 shares0Common StockSEC:0000096943-25-000093:0
1,051 shares0Common StockSEC:0000096943-25-000088:0
1,051 shares0Common StockSEC:0000096943-25-000095:0
1,051 shares0Common StockSEC:0000096943-25-000094:0
1,051 shares0Common StockSEC:0000096943-25-000091:0
1,357 shares0Common StockSEC:0000096943-25-000090:0
1,051 shares0Common StockSEC:0000096943-25-000092:0
25 of 154 declarations
关于 TELEFLEX INC
Teleflex Inc.（股票代码：TFX）是一家总部位于美国的医疗技术公司，在美国纽约证券交易所上市。对于讲法语的投资者而言，Teleflex最好被理解为一家专注于高价值医院设备的专业医疗技术制造商，而非一家广泛、全面多元化的医疗保健综合企业。其产品组合涵盖血管通路、介入产品、重症监护、麻醉、泌尿科、呼吸护理，以及其他医疗设备制造商使用的精选OEM产品。该公司起源于1943年，当时成立时是精密机械推拉控制装置的制造商，主要用于军用飞机。随着时间的推移，通过内部产品开发、地域扩张以及长期的收购和剥离，公司不断发展。Teleflex的总部位于宾夕法尼亚州韦恩市。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000096943/000009694326000019/tfx-20251231.htm?utm_source=openai) Teleflex在医疗设备领域占据着重要的利基市场地位，尤其是在手术可靠性、临床精确性和已建立的医院关系至关重要的领域。其核心业务包括用于血管通路的导管和附件、介入器械、麻醉设备、呼吸和重症监护产品，以及外科或泌尿科相关解决方案。这种组合使公司能够受益于医院的经常性需求和手术量驱动的业务，同时也使其对产品周期、定价压力、报销动态以及医疗系统采购行为保持敏感。换句话说，Teleflex并非每个类别中最大的参与者，但在几个重点细分市场中拥有可靠的品牌实力和技术深度。（[sec.gov](https://www.sec.gov/Archives/edgar/data/0000096943/000009694326000019/tfx-20251231.htm?utm_source=openai) 从地理上看，Teleflex是一家国际性企业，业务遍及美国、欧洲和其他主要医疗保健市场。近期企业发展尤为重要。2025年，Teleflex完成了对BIOTRONIK几乎所有血管介入业务的收购，扩大了其冠状动脉介入产品组合，并加强了其在不断增长的外周介入市场的存在。与此同时，公司一直在推行更广泛的战略调整，包括计划将部分业务拆分为两家公司，这表明了其投资组合简化和价值创造的议程。2025年和2026年的近期财报显示，整合工作、投资组合调整和非经常性项目目前是公司发展故事的重要组成部分。（[investors.teleflex.com](https://investors.teleflex.com/news/news-details/2025/Teleflex-Completes-Acquisition-of-BIOTRONIKs-Vascular-Intervention-Business/default.aspx?utm_source=openai) 从投资者的角度来看，Teleflex是一个处于积极转型中的防御性医疗保健股。其投资案例建立在医院已安装的特许经营权、有针对性的并购和战略重组之上，但执行风险仍然很重要。投资者可能会关注BIOTRONIK资产的整合、业务拆分举措的影响、监管和报销压力，以及心脏病介入和重症监护领域的需求趋势。（[investors.teleflex.com](https://investors.teleflex.com/news/news-details/2025/Teleflex-Reports-Third-Quarter-Financial-Results-and-Full-Year-2025-Outlook/default.aspx?utm_source=openai))
